A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study
- Carol Aghajanian
- , John A. Blessing
- , Kathleen M. Darcy
- , Gary Reid
- , Koen DeGeest
- , Stephen C. Rubin
- , Robert S. Mannel
- , Jacob Rotmensch
- , Russell J. Schilder
- , William Riordan
- Memorial Sloan-Kettering Cancer Center
- Roswell Park Cancer Institute
- Riverside Methodist Hospital
- University of Iowa
- University of Pennsylvania
- University of Oklahoma
- Rush University
- Fox Chase Cancer Center
- Takeda Pharmaceutical Company
Research output: Contribution to journal › Article › peer-review
52
Scopus
citations